|
临床试验结果不一致导致的监管复杂决策：伊布替尼适用...
2023.10.24
2023年9月，Edward R. Scheffer Cliff在《nature review clinical oncology》发表文章，题为《Complicated regulatory decision-making following inconsistent trial results the issue with ibrutinib for mantle cell lymphoma》，旨在讨论同一药物针对同一适应症...
|
